Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

Fig. 1

Retention rate over 12 months of abatacept treatment (analysis population). The retention rate estimate and 95 % CIs were computed using the Kaplan–Meier method. An event was defined as a discontinuation reported by the physician at any follow-up visit; patients who did not reach the considered time point were censored at the date of last data available; patients with only baseline data were considered as censored at first infusion date. The analysis population included patients treated in Canada, Germany, Greece, and Italy who had received at least one prior biologic agent and had a baseline clinical assessment no later than 8 days after the first administration of abatacept. CI, confidence interval

Back to article page
\